How to Vet Competitor Analysis Services for Admissions

What the Hospital Competition Literature Actually Says

Share-of-voice dashboards assume more visibility produces better admissions. The peer-reviewed hospital competition literature complicates that assumption in ways a marketing manager should read before signing another intelligence contract.

Three studies point in overlapping but non-identical directions. Using administrative data from Victoria, Australia, researchers found that hospitals facing higher competition had lower unplanned readmission rates, but competition was weakly negatively related to hospital quality when measured by mortality ¹. A 2025 study using national individual-level data from China found that hospital competition can decrease the probability of patients being readmitted within one year and increase patient satisfaction with healthcare quality ⁸. A U.S. local-market working paper reached a sharper conclusion: local competition among hospitals leads to higher patient satisfaction, but seemingly lower medical quality, with improvements concentrated in “room and board” care rather than clinical outcomes ⁹.

None of these studies examined addiction treatment centers. Two are general hospital datasets outside the United States, and the U.S. paper covers acute-care hospitals, not behavioral health. The directional signal still matters for admissions strategy: competition consistently moves satisfaction and amenity metrics up, while clinical quality signals move independently and sometimes in the opposite direction. A vendor that measures rivals only on traffic, keywords, and ad impressions will miss the axis on which competition can actually erode the buyer’s clinical positioning.

Quality-Adjusted Competitor Metrics a Credible Vendor Should Already Track

A competent competitor analysis service arrives with a metric set that reflects the split the research shows. Volume signals stay on the report because they still inform paid strategy and content gaps. They no longer sit at the top of the scorecard alone.

The metric set worth paying for tracks competitors on four layers:

• First, admission-fit indicators: publicly disclosed levels of care, accreditations, clinical staff ratios, and payer mix visible on rival websites and directory listings.
• Second, patient experience signals: review sentiment patterns, complaint themes, and how competitors respond to negative reviews over time.
• Third, claim substantiation posture: whether rivals publish outcome claims that would meet the FTC’s requirement that health-related claims be backed by competent and reliable scientific evidence ⁶, or whether they lean on the guarantee and miracle-language patterns the FTC flags as red flags ⁵.
• Fourth, mission alignment: how competitors position service mix, geographic reach, and pricing relative to their stated clinical mission, an approach grounded in the healthcare competition and strategic mission literature ⁷.

The point of layering is not academic completeness. It is that a vendor tracking only rankings and ad spend cannot tell a marketing manager whether a rival is winning admissions the buyer would actually want, or filling beds with cases the clinical team will discharge in seven days. Ask for the metric taxonomy in writing before the first deliverable.

Criterion 1: Data Provenance and Public-Source Discipline

Every data point in a competitor report should trace back to a source a compliance officer can inspect. That means named websites, filed accreditation records, published directory listings, review platforms with public URLs, ad libraries, court and licensing records, and search engine results pages captured on a stated date.

The disqualifier is any dataset the vendor cannot map to origin. Purchased lookalike audiences derived from rival intake behavior, scraped intake form submissions, third-party pixel data pulled from competitor sites, and “proprietary” panels of admissions inquiries are all provenance failures. If the vendor cannot answer where a signal came from, who collected it, and under what terms of service, the buyer inherits that ambiguity.

A working test: ask for the raw source list behind three specific claims in the pitch deck. A credible vendor produces URLs, capture dates, and collection methodology within a business day. A weak vendor sends a rewritten summary and calls the underlying data confidential.

Criterion 2: PHI and PHR Handling Under HIPAA and the Health Breach Notification Rule

HIPAA defines marketing as communications that encourage recipients to purchase or use a product or service, and generally prohibits those communications without patient authorization, subject to narrow exceptions ¹⁰. That definition is the fence line for any vendor whose work touches admissions data.

Three flows deserve separate scrutiny:

• Public data flows, such as competitor websites, ad libraries, and directory listings, carry no PHI and sit outside the marketing authorization trigger.
• PHI-adjacent flows are where risk concentrates: intake CRM exports, retargeting pixels fired from patient portal or intake pages, custom audiences built from admissions inquiries, and any segmentation that uses protected health information to shape outreach. Under HHS guidance, using PHI to encourage use of the center’s services generally requires authorization, and the vendor’s methodology must reflect that ^{10, 11}.
• Marketing outputs are the last flow, and the substantiation of what they say is a separate criterion covered below.

Storage adds a second law. Any vendor that stores identifiable health information as a vendor of personal health records or a related entity falls under the FTC’s Health Breach Notification Rule, which requires consumer notification following breaches of unsecured health information and specifies the timing, method, and content of notification ⁴. Ask directly: does the platform store any data that could qualify as a personal health record, and what is the breach notification workflow. Vagueness on either question is a disqualifier.

Criterion 3: Claim Substantiation Under FTC Health Advertising Standards

The FTC’s Health Products Compliance Guidance is explicit: advertising must be truthful and non-misleading, and before disseminating an ad, advertisers must have adequate substantiation for all objective product claims, with health-related claims generally requiring competent and reliable scientific evidence ⁶. That standard governs the buyer’s ads, and it governs any comparative claim a competitor analysis vendor recommends the buyer make.

A credible vendor’s deliverable distinguishes three claim types and treats them differently:

• Descriptive claims about competitors (levels of care offered, accreditations held, geographic footprint) require documentation from public sources.
• Comparative claims (“our program has shorter wait times than X”) require the buyer’s own substantiation before use.
• Outcome claims (“90% completion rate,” “industry-leading recovery outcomes”) require scientific evidence and, per FTC consumer guidance, should trigger scrutiny of guarantee language, miracle framing, and rapid-result promises ⁵.

The disqualifier is a vendor that hands over positioning language built on rival outcome claims without flagging substantiation gaps, or that recommends the buyer mirror a competitor’s unsubstantiated promise. Ask to see how the vendor tags claims by evidence tier in prior deliverables. If the report does not distinguish public fact from marketing assertion from unsubstantiated outcome claim, the methodology is not built for this sector.

Criterion 4: CMS and Medicare Advantage Exposure

Centers serving Medicare Advantage or Part D populations, or evaluating rivals that do, face a marketing rule surface most B2B competitor analysis vendors do not know exists. CMS defines marketing as materials used with the intent to draw a beneficiary’s attention to a plan or plans and to influence a beneficiary’s decision-making process in plan selection, and prohibits providers from offering inducements to persuade patients to enroll in a particular plan or conducting health screenings as a marketing activity ¹⁴.

The surface got wider in late 2024. CMS’s December 2024 Federal Register proposal would eliminate the content standard so that all communications materials and activities that meet the existing intent standard are considered marketing for purposes of MA and Part D marketing and communications regulations ³. Translation: educational-looking content that intends to influence plan selection gets pulled into the marketing definition, along with the submission and oversight obligations that follow ².

A qualified vendor asks in the discovery call whether the buyer’s admissions funnel touches Medicare beneficiaries and whether rival research will inform materials that could meet the intent standard. If that question never comes up, the vendor is not equipped to advise on MA-adjacent competitor moves without importing risk.

Criterion 5: Outcome-Metric Depth Beyond Share of Voice

Section 2 established the split: competition consistently moves satisfaction and amenity signals, while clinical quality moves independently. Criterion 5 turns that into a procurement test.

A vendor’s standing metric taxonomy should include admission-fit indicators (levels of care, accreditations, payer mix, clinical staff visibility), patient experience signals (review sentiment trend, complaint themes, response cadence), claim-substantiation posture (whether rivals rely on outcome guarantees the FTC would flag), and mission-alignment indicators (service mix relative to stated clinical mission, drawing on the strategic mission and patient satisfaction literature) ⁷. Volume signals stay on the report; they no longer sit at the top alone.

Ask the vendor for a redacted sample deliverable from a prior behavioral health engagement and count how many pages address non-volume metrics. A report that spends 90% of its real estate on keyword rankings, backlink counts, and ad impressions is measuring the wrong axis for admissions quality. The clinical team will discharge the wrong cases regardless of how efficiently the funnel filled.

Criterion 6: Deliverable Transparency and Methodology Documentation

The final criterion is whether the vendor’s work survives audit. Every deliverable should carry three artifacts: a methodology statement naming data sources and collection dates, a claim-tier tag on every assertion (public fact, marketing assertion, unsubstantiated outcome claim), and a change log when reports are updated.

Reproducibility is the practical test. A second analyst, given the vendor’s methodology and source list, should be able to rebuild any headline finding within a reasonable margin. If the vendor treats methodology as trade secret and asks the buyer to trust the conclusions, the report cannot be defended to compliance, clinical leadership, or a regulator who asks how a comparative claim was substantiated.

Contract language should require methodology disclosure, source retention for the contract term, and prompt cooperation with any compliance review the buyer initiates. Vendors that resist those clauses are telling the buyer what the working relationship will look like when a claim is challenged.

The Monument Settlement as an Operational Benchmark

The clearest disqualifier in the current enforcement record is a vendor that treats health data as ad-targeting fuel. In April 2024, the FTC announced a settlement with Monument, Inc., an alcohol addiction treatment firm, that banned the company from disclosing health information for advertising, required a mandated privacy program, and forced it to seek deletion of data shared with third parties ¹³. The mechanism was familiar: intake and treatment data flowing to advertising platforms through pixels and custom-audience uploads.

Two other federal anchors belong on the same risk-surface screen. The 2024 joint FDA and FTC warning against companies selling unapproved opioid cessation products made explicit that unsubstantiated therapeutic claims violate the FTC Act’s prohibition on deceptive advertising ¹². And CMS’s December 2024 Federal Register proposal would eliminate the content standard so that any communication meeting the intent standard is treated as Medicare marketing ³. A vendor should be able to walk through all three anchors and describe, in specifics, what its methodology does differently. Silence on any one is the answer.

Deceptive Recovery and Cessation Claims

The second disqualifier is a vendor that treats rival outcome claims as positioning inspiration rather than substantiation risk. The FDA and FTC’s joint action against companies marketing unapproved opioid cessation products made the standard operational: making unsubstantiated therapeutic claims is a violation of the FTC Act’s prohibition on deceptive advertising ¹². FTC consumer guidance reinforces the pattern to watch for, flagging guarantees, miracle framing, and rapid-result promises as red flags in health advertising ⁵.

In practice, that means a competitor report showing a rival’s “95% success rate” or “guaranteed recovery” language is documenting a substantiation problem, not a benchmark to match. A qualified vendor tags those claims as unsubstantiated and recommends the buyer avoid mirroring them. A weak vendor writes them into a positioning matrix and suggests the buyer needs a stronger number to compete.

The test is simple. Ask the vendor how a prior deliverable handled a rival’s outcome claim that lacked visible scientific backing. If the answer describes a competitive-response angle rather than a substantiation flag, the methodology will import risk into the buyer’s next campaign.

Patient Brokering Signals and Undisclosed Lead-Gen Relationships

The third disqualifier is behavioral-health-specific and easy to miss in a generic B2B vetting process. Competitor analysis vendors that also operate, resell, or take referral fees from lead-generation networks introduce a conflict the buyer cannot manage after the contract is signed. The same analyst mapping the rival landscape may be routing calls into it.

Screen for three signals during vetting:

1. Ask whether the vendor or any affiliate operates a call aggregator, directory, or paid referral platform serving addiction treatment.
2. Ask how the vendor’s competitor set is defined, and whether centers that decline to buy leads from an affiliated network appear in the analysis on the same terms as those that do.
3. Ask for written disclosure of any financial relationship with the rivals being analyzed, including revenue share, referral fees, or platform-placement fees.

The CMS marketing framework reinforces the general principle: inducements and undisclosed influence on beneficiary decisions are prohibited in the Medicare Advantage context, and the same instinct applies here ¹⁴. A vendor that cannot produce a clean conflict disclosure inside a week is documenting the answer.